Concepedia

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

Ronald P. Gladue, Timothy Paradis, Susan H. Cole, Carol Donovan, Robin T. Nelson, Robbin Alpert, Joe Gardner, Ed Natoli, Eileen A. Elliott, Richard M. Shepard,

Cancer Immunology Immunotherapy · 2011 · 66 citations · 21 references

DOIFull text

Open access

Concepts

References

21

Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

Robert H. Vonderheide, Keith T. Flaherty, Magi Khalil et al. · Journal of Clinical Oncology · 2007 · 513 citations

, , +16

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

Linda Diehl, Annemieke Th. den Boer, Stephen P. Schoenberger et al. · Nature Medicine · 1999 · 463 citations

, , +14

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

Ruth R. French, H.T. Claude Chan, Alison L. Tutt et al. · Nature Medicine · 1999 · 427 citations

, , +14

Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients

Robert H. Vonderheide, Janice P. Dutcher, Jeanne E. Anderson et al. · Journal of Clinical Oncology · 2001 · 225 citations

, , +17

CD40 stimulation leads to effective therapy of CD40 <sup>−</sup> tumors through induction of strong systemic cytotoxic T lymphocyte immunity

Geertje J. D. van Mierlo, Annemieke Th. den Boer, Jan Paul Medema et al. · Proceedings of the National Academy of Sciences · 2002 · 224 citations · Full text

, , +17